Keele Research Repository

Article

Fernando, IN, Lax, S, Bowden, SJ, Ahmed, I, Steven, JH, Churn, M, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Agrawal, RK, Canney, P, Stevens, A and Rea, DW (2023) Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology.

Fernando, IN, Bowden, SJ, Herring, K, Brookes, CL, Ahmed, I, Marshall, A, Grieve, R, Churn, M, Spooner, D, Latief, TN, Agrawal, RK, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Stevens, A, Goodman, A, Canney, P, Bishop, J, Ritchie, D, Dunn, J, Poole, CJ and Rea, DW (2020) Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142. pp. 52-61.

Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.